Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NAPROXEN SR TABLETS 750MG | 750MG | TABLET (EXTENDED-RELEASE) | Actual shortage | 2017-08-13 | 2017-10-05 | 19015 |
| APO-NEVIRAPINE XR | 400MG | TABLET (EXTENDED-RELEASE) | Resolved | 2017-06-06 | 2017-08-30 | 12069 |
| APO-NIFED PA - SRT 20MG | 20MG | TABLET (EXTENDED-RELEASE) | Actual shortage | 2017-08-13 | 2017-10-05 | 19018 |
| APO-NIFED PA - TAB 10MG | 10MG | TABLET | Actual shortage | 2017-08-13 | 2017-10-05 | 19021 |
| APO-NITROGLYCERIN | 0.4MG | METERED-DOSE PUMP | Resolved | 2017-03-10 | 2018-02-26 | 402 |
| APO-OFLOXACIN | 0.3% | SOLUTION | Resolved | 2017-03-10 | 2019-01-08 | 405 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2019-02-06 | 2019-03-29 | 74917 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2020-06-04 | 2020-07-28 | 116547 |
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2020-02-13 | 2020-06-02 | 106006 |
| APO-OLANZAPINE | 10MG | TABLET | Resolved | 2022-10-07 | 2022-12-05 | 171422 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-05-06 | 2023-06-02 | 191874 |
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2017-03-12 | 2017-06-05 | 677 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2019-02-24 | 2019-03-29 | 76729 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2017-11-09 | 2018-01-10 | 28689 |
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2020-06-24 | 2020-12-17 | 118769 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-10-17 | 2022-12-05 | 171886 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-07-27 | 2023-09-28 | 200180 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2025-08-28 | 2025-09-19 | 266084 |
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2019-02-06 | 2019-03-29 | 74922 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2019-02-13 | 2019-03-30 | 75623 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |